JP2000510685A - 単球化学誘引タンパク質1(mcp―1)レセプター(ccr2)に結合する抗体 - Google Patents
単球化学誘引タンパク質1(mcp―1)レセプター(ccr2)に結合する抗体Info
- Publication number
- JP2000510685A JP2000510685A JP09530879A JP53087997A JP2000510685A JP 2000510685 A JP2000510685 A JP 2000510685A JP 09530879 A JP09530879 A JP 09530879A JP 53087997 A JP53087997 A JP 53087997A JP 2000510685 A JP2000510685 A JP 2000510685A
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- mcp
- cells
- antibody
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 単球化学誘引タンパク質1(MCP−1)レセプターCCR2と結合可能 な抗体。 2. モノクローナル抗体である、請求の範囲第1項に記載の抗体。 3. アンタゴニストまたはアゴニストのいずれかとして作用することができる 請求の範囲第1項または2のいずれかに記載の抗体。 4. 機能性レセプターアンタゴニストとしてMCP−1レセプターに作用する 請求の範囲第3項に記載の抗体。 5. 機能性レセプターアゴニストとしてMCP−1レセプターに作用する請求 の範囲第3項に記載の抗体。 6. レセプターの第三の細胞外ループに存在する配列を認識する、請求の範囲 第4項に記載の抗体。 7. レセプターの第三の細胞外ループに存在する配列を認識し、レセプターの アミノ酸残基273〜292を認識する、請求の範囲第6項に記載の抗体。 8. レセプターの細胞外アミノ末端領域を認識する請求の範囲第5項に記載の 抗体。 9. レセプターの細胞外アミノ末端領域を認識し、レセプターのアミノ酸残基 24〜38を認識する請求の範囲第8項に記載の、およびレセプターの細胞外ア ミノ末端領域を認識する抗体。 10. MCP−1レセプターと結合することができ、細胞または生物学的組織 においてMCP−1レセプターの免疫沈降ができ、人工膜上に吸着されたMCP −1レセプターの検出が可能である、請求の範囲第1項〜第9項のいずれか一項 に記載の抗体。 11. 免疫蛍光法において、MCP−1レセプターを発現するMono−Ma c−1およびTHP1細胞を認識する請求の範囲第10項に記載の抗体。 12. インビトロ診断および/またはインビボ診断のための請求の範囲第1項 〜第11項のいずれか一項に記載の抗体の使用。 13. MCP−1レセプターを発現する組織および細胞クラスをスクリーニン グおよび検出するための請求の範囲第1項〜第12項のいずれか一項に記載の抗 体の使用。 14. 新薬のスクリーニングのための請求の範囲第1項〜第12項のいずれか 一項に記載の抗体の使用。 15. 請求の範囲第1項から12項のいずれかに記載の抗体を含む抗体製剤。 16. 治療に使用するための請求の範囲第1項〜第12項のいずれか一項に記 載の抗体。 17. 請求の範囲第1項〜第12項のいずれか一項に記載の抗体と担体とを含 む医薬組成物。 18. 請求の範囲第1項〜第12項のいずれか一項に記載の抗体を産生するこ とができる微生物または細胞系。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9600820A SE9600820D0 (sv) | 1996-03-01 | 1996-03-01 | Antibodies and their use |
SE9600820-6 | 1996-03-01 | ||
PCT/SE1997/000342 WO1997031949A1 (en) | 1996-03-01 | 1997-02-27 | Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2) |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000510685A true JP2000510685A (ja) | 2000-08-22 |
Family
ID=20401642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09530879A Pending JP2000510685A (ja) | 1996-03-01 | 1997-02-27 | 単球化学誘引タンパク質1(mcp―1)レセプター(ccr2)に結合する抗体 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6084075A (ja) |
EP (1) | EP0914345B1 (ja) |
JP (1) | JP2000510685A (ja) |
AT (1) | ATE258560T1 (ja) |
AU (1) | AU724037B2 (ja) |
DE (1) | DE69727382T2 (ja) |
DK (1) | DK0914345T3 (ja) |
ES (1) | ES2210496T3 (ja) |
PT (1) | PT914345E (ja) |
SE (1) | SE9600820D0 (ja) |
WO (1) | WO1997031949A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009532399A (ja) * | 2006-04-03 | 2009-09-10 | ゲオルク−アウグスト−ウニヴェルジテート・ゲッティンゲン・シュティフトゥング・エッフェントリヒェン・レッヒツ | 多発性硬化症および/または関節リウマチの処置 |
JP2018072098A (ja) * | 2016-10-27 | 2018-05-10 | 株式会社ナリス化粧品 | 真皮シミ予防・改善剤及び/又はマクロファージ誘引剤のスクリーニング方法 |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69535327T2 (de) * | 1994-01-13 | 2007-06-06 | The Regents Of The University Of California, Oakland | Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung |
US20020019026A1 (en) * | 1995-06-05 | 2002-02-14 | Daniel R. Soppet | Human g-protein receptor hgber32 |
GB9705521D0 (en) | 1997-03-18 | 1997-05-07 | Univ Sheffield | The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue |
JP2001514886A (ja) * | 1997-08-14 | 2001-09-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, アズ レプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ccr2遺伝子のミスセンス対立遺伝子によるaidsへの進行の遅延 |
CA2318405C (en) * | 1998-01-26 | 2014-01-07 | Genentech, Inc. | Antibodies to death receptor 4(dr4) and uses thereof |
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
WO2001057226A1 (en) * | 2000-02-03 | 2001-08-09 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
US6727349B1 (en) | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6488930B1 (en) * | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
EP1783227A1 (en) * | 2000-02-03 | 2007-05-09 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
AU2004208716B2 (en) * | 2000-02-03 | 2007-01-04 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
AU4574501A (en) | 2000-03-17 | 2001-10-03 | Millennium Pharm Inc | Method of inhibiting stenosis and restenosis |
WO2002072141A2 (en) * | 2001-03-09 | 2002-09-19 | William Herman | Targeted ligands |
US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
CA2449628C (en) | 2001-06-07 | 2008-05-06 | Zheng Wei | Cell migration assay |
US20040151721A1 (en) | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
US7871619B2 (en) * | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7253007B2 (en) * | 2001-11-30 | 2007-08-07 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7413866B2 (en) * | 2001-11-30 | 2008-08-19 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7442512B2 (en) * | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
AU2002357770B2 (en) * | 2001-11-30 | 2008-07-31 | Biogen Ma Inc. | Antibodies against monocyte chemotactic proteins |
US20050142539A1 (en) * | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
CA2479212A1 (en) * | 2002-03-15 | 2003-09-25 | Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
CA2507080C (en) | 2002-11-27 | 2015-01-06 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactic proteins |
EP1606251B1 (en) * | 2002-12-20 | 2009-04-08 | ChemoCentryx Inc | Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor |
US20050148507A1 (en) * | 2003-05-02 | 2005-07-07 | Boehringer Ingelheim International Gmbh | Method for the production of an N-terminally modified chemotactic factor |
US20100247540A1 (en) * | 2003-10-30 | 2010-09-30 | Chemocentryx, Inc. | Methods and Compositions For Modulating Angiogenesis |
US20080299130A1 (en) * | 2004-05-04 | 2008-12-04 | University Of Kentucky Research Foundation | Methods And Compositions For The Treatment Of Ocular Neovascularization |
WO2006109301A2 (en) * | 2005-04-15 | 2006-10-19 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |
EP1871804B1 (en) * | 2005-04-21 | 2013-08-28 | ChemoCentryx, Inc. | Antibodies that bind ccx-ckr2 |
US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
EA200970350A1 (ru) * | 2006-10-05 | 2009-12-30 | Сентокор Орто Байотек, Инк. | Антагонисты ccr2 для лечения фиброза |
PE20110774A1 (es) | 2008-08-18 | 2011-10-13 | Amgen Fremont Inc | Anticuerpos para ccr2 |
WO2014064192A1 (en) | 2012-10-26 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction |
WO2016081801A1 (en) * | 2014-11-21 | 2016-05-26 | Millennium Pharmaceuticals, Inc. | Use of an anti-ccr2 antagonist in the treatment of an infectious disease |
US11846629B2 (en) | 2016-09-20 | 2023-12-19 | Tulane University | MonoMac-1 cells expressing CD16 and CD163 |
CA3045296A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
US10980739B2 (en) | 2016-12-14 | 2021-04-20 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
AU2018256406A1 (en) | 2017-04-19 | 2019-10-17 | Marengo Therapeutics, Inc. | Multispecific molecules and uses thereof |
US20200377571A1 (en) | 2017-12-08 | 2020-12-03 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
JP2021534101A (ja) | 2018-08-09 | 2021-12-09 | ヴェルソー セラピューティクス, インコーポレイテッド | Ccr2及びcsf1rを標的とするためのオリゴヌクレオチド組成物ならびにその使用 |
CA3113826A1 (en) | 2018-09-27 | 2020-04-02 | Marengo Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
TW202233251A (zh) | 2020-11-09 | 2022-09-01 | 日商武田藥品工業股份有限公司 | 抗體藥物綴合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0669979B1 (en) * | 1992-11-10 | 2005-10-12 | Genentech, Inc. | C-c ckr-1, c-c chemokine receptor |
US5652133A (en) * | 1993-01-28 | 1997-07-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Cloning and expression of the human macrophage inflammatory protein-1.alpha.α) /rantes receptor |
DE69535327T2 (de) * | 1994-01-13 | 2007-06-06 | The Regents Of The University Of California, Oakland | Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung |
DE19503303A1 (de) * | 1995-02-02 | 1996-08-08 | Teves Gmbh Alfred | Filtersystem mit selbsttätigem Filterwechsel für Kraftfahrzeuge |
-
1996
- 1996-03-01 SE SE9600820A patent/SE9600820D0/xx unknown
-
1997
- 1997-02-27 WO PCT/SE1997/000342 patent/WO1997031949A1/en active IP Right Grant
- 1997-02-27 ES ES97906403T patent/ES2210496T3/es not_active Expired - Lifetime
- 1997-02-27 DK DK97906403T patent/DK0914345T3/da active
- 1997-02-27 PT PT97906403T patent/PT914345E/pt unknown
- 1997-02-27 EP EP97906403A patent/EP0914345B1/en not_active Expired - Lifetime
- 1997-02-27 DE DE69727382T patent/DE69727382T2/de not_active Expired - Fee Related
- 1997-02-27 AU AU21104/97A patent/AU724037B2/en not_active Ceased
- 1997-02-27 JP JP09530879A patent/JP2000510685A/ja active Pending
- 1997-02-27 AT AT97906403T patent/ATE258560T1/de not_active IP Right Cessation
- 1997-02-28 US US08/734,171 patent/US6084075A/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009532399A (ja) * | 2006-04-03 | 2009-09-10 | ゲオルク−アウグスト−ウニヴェルジテート・ゲッティンゲン・シュティフトゥング・エッフェントリヒェン・レッヒツ | 多発性硬化症および/または関節リウマチの処置 |
JP2018072098A (ja) * | 2016-10-27 | 2018-05-10 | 株式会社ナリス化粧品 | 真皮シミ予防・改善剤及び/又はマクロファージ誘引剤のスクリーニング方法 |
Also Published As
Publication number | Publication date |
---|---|
WO1997031949A1 (en) | 1997-09-04 |
DE69727382D1 (de) | 2004-03-04 |
ATE258560T1 (de) | 2004-02-15 |
EP0914345B1 (en) | 2004-01-28 |
EP0914345A1 (en) | 1999-05-12 |
US6084075A (en) | 2000-07-04 |
ES2210496T3 (es) | 2004-07-01 |
DK0914345T3 (da) | 2004-05-10 |
SE9600820D0 (sv) | 1996-03-01 |
AU2110497A (en) | 1997-09-16 |
PT914345E (pt) | 2004-05-31 |
DE69727382T2 (de) | 2004-11-04 |
AU724037B2 (en) | 2000-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000510685A (ja) | 単球化学誘引タンパク質1(mcp―1)レセプター(ccr2)に結合する抗体 | |
Menten et al. | Macrophage inflammatory protein-1 | |
Huang et al. | Molecular and biological characterization of the murine leukotriene B4 receptor expressed on eosinophils | |
US7396911B2 (en) | Chimeric polypeptides containing chemokine domains | |
US7138117B1 (en) | Anti-CCR4 antibodies and methods of use therefor | |
Taylor | Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases | |
US6756035B2 (en) | Anti-CCR1 antibodies and methods of use therefor | |
JP2002521021A (ja) | 抗−ccr2抗体及びその使用方法 | |
JP2002513388A (ja) | Cxcr3ケモカイン受容体、抗体、核酸および使用方法 | |
EP1233785A1 (en) | "bonzo" chemokine receptor antibodies and ligands | |
JPH04500970A (ja) | マクロファージ由来炎症メディエーター (mip―2) | |
US20090252705A1 (en) | IL-6/IL-6R Fusion Protein | |
KR20010089764A (ko) | 인터류킨-17과 관련된 포유류의 사이토카인, 이를코딩하는 폴리뉴클레오티드 및 이의 용도 | |
US6852508B1 (en) | Chemokine with amino-terminal modifications | |
JPH09502725A (ja) | Il8阻害剤 | |
US6692922B2 (en) | Method for identifying agents which modulate chemokine “MEC”-induced functions of CCR3 | |
Repke et al. | Chemokines as targets for pharmacological intervention | |
AU2002319524A1 (en) | A fusion protein | |
JP2003517810A (ja) | 抗−ccr1抗体およびその使用方法 | |
Kurdowska et al. | An anti-interleukin 8 monoclonal antibody that interferes with the binding of interleukin 8 to cellular receptors and the activation of human blood neutrophils | |
US20110028399A1 (en) | Citrullinated cytokines | |
US6824781B2 (en) | Method of impairing movement of a CLA + memeory T-cell within or to the skin of a mammal by administering a CTACK antagonist | |
JP4116087B2 (ja) | 新規マウスcxcケモカインレセプター | |
Inflammation | A Non-Glycosaminoglycan-Binding Variant | |
JP2001161369A (ja) | ケモカインhvc002の有する活性を阻害する抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060620 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060919 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070517 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070820 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071009 |